Bayer Schering Pharma, Prometheus Reach Agreement on Oncology Mutational Analyses

The agreement broadens an earlier molecular and pathway activation profiling deal directed at cancer that the two firms had reached in March.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories